

References

I-161

1. Chang T, Shiah H, Yang C, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. *Cancer Chemother and Pharmacol.* 2015;75(3):579-586.
2. Koeller J, Surinach A, Arikian S.R, et al. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. *Ther Adv Med Oncol.* 2020:12.
3. Wang-Gillam A, Hubner RA, Siveke, JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer.* 2019;108:78-87.
4. Irinotecan In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 3, 2017.
5. Clinical Pharmacology™ Compendium. Tampa FL: Gold Standard, Inc. Irinotecan Liposomal.
6. Micromedex DrugDex Compendium®. 2022. Irinotecan Liposome (Onivyde).
7. National Comprehensive Cancer Network (NCCN). Onivyde. NCCN Drugs and Biologics Compendium®. 2022.
8. Onivyde (irinotecan liposome injection) for intravenous use [package insert]. Ipsen Biopharmaceuticals, Inc. Basking Ridge, NJ. Revised 06/2017.